We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MTD:NYSEMettler-Toledo International, Inc. Analysis

Data as of 2026-05-25 - not real-time

$1,103.09

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Mettler‑Toledo (MTD) is trading at $1,103, well under its 20‑day ($1,165), 50‑day ($1,229) and 200‑day ($1,328) moving averages, signaling a bearish technical backdrop. The RSI sits at 41, hinting at modest oversold pressure, while the MACD histogram remains negative, reinforcing the downtrend. Volatility is elevated at 58% over the past 30 days and beta (~1.06) suggests the stock moves slightly more than the market. Fundamentally, the company delivered 7.2% YoY revenue growth in Q1, beat consensus earnings, and trades at a forward PE of 21.5 versus an industry average of 27.6, indicating relative valuation attractiveness.
Despite the technical weakness, the earnings beat, solid margin profile (gross margin ~59%) and a forward‑looking earnings trajectory support a positive outlook. However, the DCF‑derived fair value of $431 starkly contrasts with the current price, flagging potential overvaluation, and the absence of any dividend eliminates income‑focused appeal. Investors should weigh the short‑term price weakness against the medium‑term growth narrative.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price below key moving averages and bearish MACD
  • Q1 earnings beat and 7.2% revenue growth
  • High short‑term volatility and proximity to support level

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Forward PE advantage over industry peers
  • Sustained revenue and margin expansion
  • Improving earnings guidance and solid cash flow generation

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • DCF fair value indicates substantial price correction needed
  • Strong market position in precision instruments across multiple geographies
  • Absence of dividend and elevated valuation metrics temper upside potential

Key Metrics & Analysis

Financial Health

Revenue Growth7.20%
Profit Margin21.40%
P/E Ratio25.9
ROA20.57%
P/B Ratio-532.1
Op. Cash Flow$901.1M
Free Cash Flow$615.0M
Industry P/E27.6

Technical Analysis

TrendBearish
RSI40.9
Support$1,023.05
Resistance$1,347.03
MA 20$1,165.33
MA 50$1,228.93
MA 200$1,328.19
MACDBearish
VolumeIncreasing
Fear & Greed Index91.71

Valuation

Fair Value$430.86
Target Price$1,327.83
Upside/Downside20.37%
GradeFair
TypeBlend

Risk Assessment

Beta1.06
Volatility58.05%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.